• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新冠病毒会影响多发性硬化症的进展吗？

Could Sars-Cov2 affect MS progression?

机构信息

Otolaryngology Department, University of Perugia, Perugia, Italy; Neuroinflammation Lab, Queen Square UCL Neurology, London, UK.

Department of Experimental Medicine, University of Perugia, Perugia, Italy.

出版信息

Mult Scler Relat Disord. 2020 Nov;46:102540. doi: 10.1016/j.msard.2020.102540. Epub 2020 Sep 29.

DOI:10.1016/j.msard.2020.102540
PMID:33032060
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7524432/
Abstract

A long-term neurologic sequela arising from COVID-19 infection in multiple sclerosis (MS) patients could be related both to the increase of cytokines and the activation of NLRP3 inflammasome by the Sars-CoV2. These two mechanisms may cause a worsening of MS several months after the resolution of the infection.

摘要

由 COVID-19 感染引起的多发性硬化症（MS）患者的长期神经后遗症可能与细胞因子的增加以及 Sars-CoV2 激活 NLRP3 炎性体有关。这两种机制可能会导致感染消退后数月内 MS 病情恶化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cc1/7524432/6035ca70499c/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cc1/7524432/6035ca70499c/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cc1/7524432/6035ca70499c/gr1_lrg.jpg

相似文献

1
Could Sars-Cov2 affect MS progression?新冠病毒会影响多发性硬化症的进展吗？
Mult Scler Relat Disord. 2020 Nov;46:102540. doi: 10.1016/j.msard.2020.102540. Epub 2020 Sep 29.
2
Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?超越 COVID-19：接受抗 CD20 治疗的多发性硬化症/视神经脊髓炎谱系疾病患者是否会产生 SARS-CoV2 抗体？
Mult Scler Relat Disord. 2020 Nov;46:102482. doi: 10.1016/j.msard.2020.102482. Epub 2020 Sep 3.
3
Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets.接受克拉屈滨片治疗的多发性硬化症患者感染新冠病毒后的良好预后。
Mult Scler Relat Disord. 2020 Nov;46:102469. doi: 10.1016/j.msard.2020.102469. Epub 2020 Aug 27.
4
Modulation of the NLRP3 inflammasome by Sars-CoV-2 Envelope protein.Sars-CoV-2 包膜蛋白对 NLRP3 炎性小体的调节。
Sci Rep. 2021 Dec 24;11(1):24432. doi: 10.1038/s41598-021-04133-7.
5
SARS-CoV-2 viroporin encoded by ORF3a triggers the NLRP3 inflammatory pathway.SARS-CoV-2 病毒蛋白 3a 通过编码的 viroporin 触发 NLRP3 炎症途径。
Virology. 2022 Mar;568:13-22. doi: 10.1016/j.virol.2022.01.003. Epub 2022 Jan 17.
6
The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies.NLRP3 炎性小体与 COVID-19：激活、发病机制和治疗策略。
Cytokine Growth Factor Rev. 2021 Oct;61:2-15. doi: 10.1016/j.cytogfr.2021.06.002. Epub 2021 Jun 18.
7
Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications.白细胞介素-1 和 NLRP3 炎性体在 COVID-19 中的作用：发病机制和治疗意义。
EBioMedicine. 2022 Nov;85:104299. doi: 10.1016/j.ebiom.2022.104299. Epub 2022 Oct 6.
8
SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1.SARS-CoV-2 非结构蛋白 6 通过靶向 ATP6AP1 触发 NLRP3 依赖性细胞焦亡。
Cell Death Differ. 2022 Jun;29(6):1240-1254. doi: 10.1038/s41418-021-00916-7. Epub 2022 Jan 8.
9
Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients.炎症小体在 SARS-CoV-2 感染时被激活，并与 COVID-19 患者的严重程度相关。
J Exp Med. 2021 Mar 1;218(3). doi: 10.1084/jem.20201707.
10
Persistent Oxidative Stress and Inflammasome Activation in CD14CD16 Monocytes From COVID-19 Patients.新冠肺炎患者 CD14+CD16+单核细胞中持续的氧化应激和炎性体激活。
Front Immunol. 2022 Jan 14;12:799558. doi: 10.3389/fimmu.2021.799558. eCollection 2021.

引用本文的文献

1
Tonabersat Significantly Reduces Disease Progression in an Experimental Mouse Model of Multiple Sclerosis.托纳昔巴特显著减缓多发性硬化症实验小鼠模型的疾病进展。
Int J Mol Sci. 2023 Dec 14;24(24):17454. doi: 10.3390/ijms242417454.
2
From Animal Models to Clinical Trials: The Potential of Antimicrobials in Multiple Sclerosis Treatment.从动物模型到临床试验：抗菌药物在多发性硬化症治疗中的潜力
Biomedicines. 2023 Nov 16;11(11):3069. doi: 10.3390/biomedicines11113069.
3
COVID-19 and its implications on the clinico-radiological course of multiple sclerosis: A case-control study.

本文引用的文献

1
IFN-γ and TNF-α drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 lungs and inflammatory diseases with tissue inflammation.IFN-γ 和 TNF-α 驱动严重 COVID-19 肺部和伴有组织炎症的炎症性疾病中 CXCL10+CCL2+巨噬细胞表型的扩增。
Genome Med. 2021 Apr 20;13(1):64. doi: 10.1186/s13073-021-00881-3.
2
Role of inflammasomes in multiple sclerosis and their potential as therapeutic targets.炎症小体在多发性硬化症中的作用及其作为治疗靶点的潜力。
J Neuroinflammation. 2020 Sep 2;17(1):260. doi: 10.1186/s12974-020-01944-9.
3
Disease-Modifying Therapies During the COVID-19 Outbreak: A Narrative Review of International and National Recommendations.
新型冠状病毒肺炎及其对多发性硬化症临床放射学病程的影响：一项病例对照研究。
Med Clin (Engl Ed). 2023 Mar 10;160(5):187-192. doi: 10.1016/j.medcle.2022.06.021. Epub 2023 Mar 3.
4
Nasal Microbiota and Neuroinflammation: Relationship between Nasal Flora and Multiple Sclerosis Onset/Progression.鼻腔微生物群与神经炎症：鼻腔菌群与多发性硬化症发病/进展之间的关系。
Life (Basel). 2022 Dec 7;12(12):2043. doi: 10.3390/life12122043.
5
COVID-19 and its implications on the clinico-radiological course of multiple sclerosis: A case-control study.新型冠状病毒肺炎及其对多发性硬化临床-放射学病程的影响：一项病例对照研究。
Med Clin (Barc). 2023 Mar 10;160(5):187-192. doi: 10.1016/j.medcli.2022.06.020. Epub 2022 Aug 10.
6
SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19.SARS-CoV-2 感染多发性硬化症患者：与 COVID-19 治疗、辅助疗法和疫苗的相互作用。
J Neurol. 2022 Sep;269(9):4581-4603. doi: 10.1007/s00415-022-11237-1. Epub 2022 Jul 5.
7
Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study.COVID-19 是否会增加长期缓解-复发型多发性硬化症的临床活动？一项队列研究。
BMC Neurol. 2022 Feb 22;22(1):64. doi: 10.1186/s12883-022-02590-9.
8
Characteristics of COVID-19 in patients with multiple sclerosis.多发性硬化症患者的 COVID-19 特征。
Mult Scler Relat Disord. 2022 Jan;57:103437. doi: 10.1016/j.msard.2021.103437. Epub 2021 Nov 30.
9
Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?多发性硬化症与 SARS-CoV-2：相互作用开始了吗？
Front Immunol. 2021 Sep 27;12:755333. doi: 10.3389/fimmu.2021.755333. eCollection 2021.
10
Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia.在新冠疫情时代管理多发性硬化症：沙特阿拉伯专家小组对文献的回顾和共识报告。
Mult Scler Relat Disord. 2021 Jun;51:102925. doi: 10.1016/j.msard.2021.102925. Epub 2021 Mar 25.
新冠疫情期间的疾病修正疗法：国际和国内建议的叙述性综述
Int J MS Care. 2020 Jul-Aug;22(4):151-157. doi: 10.7224/1537-2073.2020-037. Epub 2020 May 18.
4
Asymptomatic and Symptomatic Patients With Non-severe Coronavirus Disease (COVID-19) Have Similar Clinical Features and Virological Courses: A Retrospective Single Center Study.无症状和轻症冠状病毒病（COVID-19）患者具有相似的临床特征和病毒学病程：一项回顾性单中心研究
Front Microbiol. 2020 Jun 26;11:1570. doi: 10.3389/fmicb.2020.01570. eCollection 2020.
5
Severe COVID-19: NLRP3 Inflammasome Dysregulated.严重 COVID-19：NLRP3 炎性小体失调。
Front Immunol. 2020 Jun 26;11:1580. doi: 10.3389/fimmu.2020.01580. eCollection 2020.
6
Targeting the NLRP3 Inflammasome in Severe COVID-19.针对严重 COVID-19 的 NLRP3 炎性小体。
Front Immunol. 2020 Jun 23;11:1518. doi: 10.3389/fimmu.2020.01518. eCollection 2020.
7
COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination.新型冠状病毒肺炎免疫病理学与中枢神经系统：对多发性硬化症及其他伴有脱髓鞘的自身免疫性疾病的影响
Brain Sci. 2020 Jun 4;10(6):345. doi: 10.3390/brainsci10060345.
8
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.COVID-19 患者的病理性炎症：单核细胞和巨噬细胞的关键作用。
Nat Rev Immunol. 2020 Jun;20(6):355-362. doi: 10.1038/s41577-020-0331-4. Epub 2020 May 6.
9
An Italian programme for COVID-19 infection in multiple sclerosis.一项针对多发性硬化症患者新冠病毒感染情况的意大利项目。
Lancet Neurol. 2020 Jun;19(6):481-482. doi: 10.1016/S1474-4422(20)30147-2. Epub 2020 Apr 30.
10
Variants in NLRP3 and NLRC4 inflammasome associate with susceptibility and severity of multiple sclerosis.NLRP3 和 NLRC4 炎症小体的变异与多发性硬化症的易感性和严重程度相关。
Mult Scler Relat Disord. 2019 Apr;29:26-34. doi: 10.1016/j.msard.2019.01.023. Epub 2019 Jan 11.